133 related articles for article (PubMed ID: 19048549)
1. [Double blockade of the renin-angiotensin system (RAS): what has the ONTARGET study taught us?].
Del Vecchio L
G Ital Nefrol; 2008; 25(6):609. PubMed ID: 19048549
[No Abstract] [Full Text] [Related]
2. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
[TBL] [Abstract][Full Text] [Related]
3. Is therapy of people with chronic kidney disease ONTARGET?
Mann JF; Tobe S; Teo KK; Yusuf S
Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
[No Abstract] [Full Text] [Related]
4. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
Middeke M
Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
[No Abstract] [Full Text] [Related]
5. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
[TBL] [Abstract][Full Text] [Related]
6. ONTARGET should not be over interpreted.
Abutaleb N
Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
[No Abstract] [Full Text] [Related]
7. [The ONTARGET trial].
Verdecchia P; Terrosu P
G Ital Cardiol (Rome); 2009 Feb; 10(2):67-72. PubMed ID: 19348142
[No Abstract] [Full Text] [Related]
8. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Serebruany VL; Atar D; Hanley DF
Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
[No Abstract] [Full Text] [Related]
9. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
[TBL] [Abstract][Full Text] [Related]
11. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
[No Abstract] [Full Text] [Related]
12. Proteinuria: Is the ONTARGET renal substudy actually off target?
Ruggenenti P; Remuzzi G
Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
[No Abstract] [Full Text] [Related]
13. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
Düsing R; Nitschmann S
Internist (Berl); 2008 Sep; 49(9):1137-40. PubMed ID: 18665340
[No Abstract] [Full Text] [Related]
14. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
[TBL] [Abstract][Full Text] [Related]
15. Focus on the ONTARGET results.
Elliott HL
J Hypertens Suppl; 2009 Jun; 27(2):S8-S10. PubMed ID: 19491625
[TBL] [Abstract][Full Text] [Related]
16. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
17. ONTARGET: How much RAS inhibition is enough?
Weder AB
Curr Hypertens Rep; 2009 Feb; 11(1):7-9. PubMed ID: 19146793
[No Abstract] [Full Text] [Related]
18. Renin-angiotensin blockade and kidney disease.
Sarafidis PA; Bakris GL
Lancet; 2008 Aug; 372(9638):511-2. PubMed ID: 18707969
[No Abstract] [Full Text] [Related]
19. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Baumhäkel M; Böhm M
Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
[TBL] [Abstract][Full Text] [Related]
20. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
Mancia G; Unger T; Zanchetti A
J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
[No Abstract] [Full Text] [Related]
[Next] [New Search]
